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Fifteen new quinazolinone derivatives bearing benzenesulfonamide moiety with variable acetamide tail
were synthesized. The structures assigned to the products were concordant with the microanalytical and
spectral data. Compounds 4e18 were screened for their ability to induce the antioxidant enzyme NAD(P)
H: quinone oxidoreductase 1 (NQO1) in cells, a classical target for transcription factor nuclear factor
erythroid 2-related factor 2 (Nrf2). The 2-((6,8-diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(3,4,5-trimethoxyphenyl) acetamide 15 showed the most potent NQO1
inducer activity in vitro. Compound 15 had low toxicity in mice (LD50 ¼ 500 mg/kg). It also reduced the
damaging effects of gamma radiation, as assessed by the levels of Nrf2, NQO1, reactive oxygen species
(ROS) and malondialdehyde (MDA) in liver tissues. In addition, compound 15 showed amelioration in the
complete blood count of irradiated mice and enhanced survival over a period of 30 days following
irradiation. Molecular docking of 15 inside the Nrf2-binding site of Kelch-like ECH associated protein 1
(Keap1), the main negative regulator of Nrf2, showed the same binding interactions as that of the co-
crystallized ligand considering the binding possibilities and energy scores. These findings suggest that
compound 15 could be considered as a promising antioxidant and radiomodulatory agent.
© 2020 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The extensive use of radiotherapy and the damage caused to the
surrounding normal organs have provoked researchers to find new
strategies to protect normal tissues from radiation hazards [1,2].
The risk of injury from radiation can diminish the value of radio-
therapy and contribute to complications for long-term cancer sur-
vivors [3]. Ionizing radiation interrupts cell functions through
radiolysis of water and the production of reactive oxygen species
(ROS) or reactive nitrogen species (RNS) [4,5]. Excessive production
of ROS and RNS promotes oxidative stress, which can affect all
cellular components, including single or double DNA strand breaksorab).
r Masson SAS. This is an open acc[6]. This ROS-mediated toxicity can lead to mutations and conse-
quently cause cardiovascular, neurological toxicities and sexual
dysfunction as well as cancer [7e10]. In order to reduce these
radiation-induced side effects, radioprotective drugs are used [11].
Also, the use of multi-target antioxidants that act as radioprotectors
can help limit normal tissue damage caused by ionizing radiation
[12e14].
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a tran-
scription factor that regulates the expression of various antioxidant
proteins to protect against oxidative damage in the cell [15]. The
abundance of Nrf2 is negatively regulated by Kelch-like ECH asso-
ciated protein 1 (Keap1), a substrate adaptor for a Cullin3/Rbx1
ubiquitin ligase that binds and continuously targets Nrf2 for ubiq-
uitination and proteasomal degradation [16e18]. Under conditions
of oxidative stress, redox-sensitive cysteine sensors of Keap1 are
modified leading to loss of, its ability to target Nrf2 for degradation;ess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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transcription of its downstream target genes, such as NAD(P)H:
quinone oxidoreductase1 (NQO1) [19].
Quinazolinone is a strategic scaffold that has a wide range of
pharmacological activities such as antioxidant, anti-inflammatory
and anticancer activities [20e23]. Sulfonamides, in addition to
their use as antibiotics [24e27], have many pharmacological ac-
tivities and can be used as antiviral [28], anti-inflammatory [29],
antioxidant [30,31], and anticancer agents [32e35]. These versatile
pharmacological activities make the two chemical classes excellent
candidates for developing newmulti-target agents through a slight
alteration in the structure that might lead to diversity in the bio-
logical activity [20,36,37]. In addition, numerous studies have
revealed iodine to be a potent antioxidant with higher potency than
that of ascorbic acid [38,39]. Iodine can act as an electron donor that
quenches ROS, such as OH and H2O2 [40], or decreases the
damaging effects of ROS, thus increasing the total antioxidant sta-
tus in human serum [41].
In this context, it seemed of interest to search for new com-
pounds with the ability to scavenge ROS and protect cells. A series
of new 6,8-diiodoquinazolin-4(3H)-one conjugated to benzene-
sulfonamide was synthesized by the introduction of the sulfon-
amide group at the N-3 of quinazolinone with the incorporation of
varying acetamide terminal aimed at exploring the potential anti-
oxidant and radioprotective activity. The antioxidant potential of
the target compounds was first measured using a quantitative and
robust NQO1 inducer activity bioassay in cells. Acute toxicity study
for the most active compound was then performed in vivo. A non-
toxic dose was subsequently selected to investigate the potential
protective effect against whole-body gamma irradiation-induced
oxidative stress in experimental mice. All groups were observed
30 days after irradiation for survival and weight changes. Addi-
tionally, molecular docking was performed inside the Nrf2-binding
site of Keap1 to gain insights into the molecular interactions and
possible mode of action.
2. Results and discussion
2.1. Chemistry
Scheme 1 shows the synthesis of thioacetamide quinazolinone
benzenesulfonamide derivatives 5e18. The starting material 4-
(6,8-diiodo-2-mercapto-4- oxoquinazolin-3(4H)-yl) benzenesulfo-
namide 4 was prepared from the reaction of 4-
isothiocyanatobenzenesulfonamide 2 [42] and 2-amino-3,5-
diiodobenzoic acid 3. The coupling of 4 with the 2-chloro-N-
substituted acetamide in dry acetone and anhydrous K2CO3 yielded
the corresponding 2-((6,8-diiodo-4-oxo-3-(4-sulfamoylphenyl)-
3,4-dihydroquinazolin-2-yl)thio)-N-substituted acetamide 5e18. IR
spectra of 5e18 displayed additional NH, CH2 aliphatic and CO
bands at their specified regions. 1H NMR spectra of 5e18 revealed
the acetamide group through the presence of two singlets, one at
4.17e4.31 ppm referring to the CH2 and the other at
9.66e11.21 ppm attributed to the NH protons with the disappear-
ance of SH singlet of 4 at 1.97 ppm. 13C NMR of 5e18 exhibited two
signals peculiar to the CH2 and CO carbons. 1H NMR spectra of 6e8
displayed singlets at 2.21, 2.28 and 2.30 ppm assigned to the CH3
group at the ortho,meta and para-positions of the phenyl group. 13C
NMR of 6e8 showed signals at 16.32, 24.13 and 19.21 ppm for the
CH3 group. 1H NMR spectra of 9e11 revealed triplets at 1.31, 1.20
and 1.15 ppm attributed to the CH3 ethyl, and quartet at 2.54, 2.58
and 2.55 ppm referring to the CH2 ethyl at the ortho,meta and para-
positions. 13C NMR of 9e11 showed two signals at 14.67, 15.21, 17.12
due to CH3 ethyl and 24.23, 24.10, 29.40 due to the CH2 ethyl
groups, respectively. 1H NMR spectra of 12 revealed singlet at3.75 ppm attributed to the OCH3 protons, while 13C NMR of 12
showed a signal at 54.26 ppm due to the OCH3 carbon. 1H NMR
spectra of 13 revealed triplet at 1.27 ppm and quartet at 3.97 ppm
due to the ethoxy group. 1H NMR spectra of 14 revealed a singlet at
3.74 ppm due to the 2OCH3 protons, while 15 revealed two singlets
at 3.70 and 3.81 ppm due to the 3OCH3 protons. IR of 16e18 showed
NO2 bands.
2.2. Biological activity
2.2.1. In vitro screening
The antioxidant activity of compounds 4e18was screened using
the NQO1 inducer activity assay. The Concentration of the novel
compounds to Double the specific enzyme activity of NQO1 (CD
value) was used as a measure of inducer potency and results ob-
tained are presented in Fig. 1 & Table 1. Evaluation of the NQO1
inducer activity showed that compounds 4, 8, 9, 11 and 13 were
inactive, whereas compounds 5, 6, 7, 10, 12, 14 and 18 had activity;
however, CD value was not reached. Compounds 15 (CD ¼ 20 mM),
and 17 (CD ¼ 50 mM) showed concentration-dependent inducer
activity. These diiodoquinazolinones represent a new chemical
class of NQO1 inducers, thus adding to the existing knowledge of
the diversity of the many chemical scaffolds that have been re-
ported to induce this antioxidant enzyme. The classical NQO1 in-
ducers are primarily oxidants and electrophiles or other
compounds that react (or are metabolized to products that react)
and chemically modify cysteine sensors of Keap1 [43]. A new
generation of NQO1 inducers is also emerging, that of noncovalent
small-molecule modulators of the Keap1eNrf2 protein-protein
interaction [44e46]. Because our diiodoquinazolinones have
some common features with the Keap1eNrf2 protein-protein
interaction inhibitors, in this study we tested the potential ability
of these compounds to directly disrupt the binding of Keap1 to Nrf2
by molecular modeling (see section 2.3).
2.2.2. In vivo evaluation
2.2.2.1. Determination of toxicity (lethal dose fifty, LD50) of com-
pound 15. The most promising compound, 15, was investigated
in vivo for acute toxicity (LD50) in albino mice, and the value was
found to be 500 mg/kg body weight (i.p.). Subsequently, one-tenth
of this dose was selected as the therapeutic dose for further eval-
uation of the potential radioprotective effects of compound 15.
2.2.2.2. Evaluation of the radiomodulatory effect of compound 15 in
mice. Four groups of mice were used, the first group served as
control, the second groupwas irradiated at a dose of 7 Gy as a single
dose, the third group was injected i.p. with compound 15 only for 5
consecutive days and the last group received compound 15 then
exposed to 7 Gy of gamma radiation. After 3 days from irradiation,
five mice were checked for liver and hematopoietic system toxic-
ities. The residual mice in all groups were monitored over 30 days
to evaluate the survival rate and body weight changes.
2.2.2.2.1. The effect of compound 15 on radiation-induced liver
toxicity. Gamma radiation-induced hepatic oxidative stress as
shown by a significant increase in hepatic levels of nuclear Nrf2
(1.3-fold), NQO1 (3.2-fold), ROS (1.5-fold) and the lipid peroxida-
tion product malondialdehyde (MDA) (2-fold) as compared to non-
irradiated (control) mice. This was in agreement with other studies
[2,47].
Ionizing radiation is believed to induce damage through the
generation of ROS, resulting in an imbalance in the oxidant/anti-
oxidant ratio in cells [8,48]. In the current experiment, the presence
of ROS-mediated damage was confirmed by the increase in MDA
levels in irradiated liver, in addition to the increase in the expres-
sion of the enzymatic antioxidant system. Moreover, these results
Scheme 1. The synthetic pathways for the development of the diiodoquinazolinone derivatives 4e18.
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sponses to radiation exposure [49]. Once Nrf2 translocates to the
nucleus it induces expression of endogenous antioxidant enzymes,
such as NQO1 [50], a flavoprotein involved in cellular protection
against oxidative stress [51].
Treatment of non-irradiated mice with compound 15 led to an
increase in NQO1 and ROS levels and a decrease in Nrf2, with nosignificant change in MDA level as compared to normal (non-irra-
diated) mice (Fig. 2). A significant increase in Nrf2 levels (19%) as
well decrease in the levels of NQO1 (30%), ROS (23%) and MDA
(28%) was observed in irradiated mice livers treated with com-
pound 15when compared to the group subjected to radiation alone
(Fig. 2). Moreover, treatment with compound 15 improved both
survival and body weight of the animals following irradiation
Fig. 1. Concentration dependence of the NQO1 inducer activity of compounds 4e18.
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irradiated mice. The present results indicate that compound 15 has
an antioxidant capacity as the treatment of irradiated mice with 15
prevents oxidative stress, reducing the increase in lipid peroxida-
tion markers and maintaining the expression of Nrf2 compared
with the irradiated group suggesting improved hepatic antioxidant
capacity. Hence, compound 15 validated its radiomodulatory and
antioxidant effect through its main structure; quinazolinone and
sulfonamide that goes in line with Soliman et al. [52]. Also, this
finding was reinforced by Cuadrado and his colleagues, who
emphasized the importance of therapeutic targeting for Nrf2
because of its resourceful cytoprotective roles against a plethora of
diseases that are associated with oxidative stress [53].
At the same time, it was found that NQO1 expression levels of
irradiated mice treated with 15 were significantly lower as
compared to vehicle-treated irradiated ones, but still significantly
higher than normal levels. Interestingly, the levels of NQO1 in all
experimental groups correlate with the levels of ROS, suggesting
ROS involvement in the NQO1 induction. The lower levels of NQO1
and ROS in the irradiated group that also received 15 could be the
results of increased antioxidant capacity due to Nrf2 activation [54].Table 1
NQO1 inducer activity and CD values of compounds 4e18.
Conc. (mM) Compound no.
4 5 6 7 8 9 10
0.313 NR NR NR NR NR 0.99 1.03
0.4 1.01 1.03 1.04 1.05 1.01 NR NR
0.625 NR NR NR NR NR 0.97 1.02
0.8 1.04 1.00 1.04 1.01 0.99 NR NR
1.25 NR NR NR NR NR 0.99 1.05
1.6 1.06 1.03 1.04 1.04 0.99 NR NR
2.5 NR NR NR NR NR 0.97 1.04
3.125 1.01 1.06 1.06 1.05 0.97 NR NR
5 NR NR NR NR NR 1.01 1.04
6.25 1.02 1.11 1.13 1.06 0.99 NR NR
10 NR NR NR NR NR 1.01 1.09
12.5 1.06 1.18 1.27 1.14 1.00 NR NR
20 NR NR NR NR NR 1.01 1.15
25 1.05 1.26 1.31 1.27 1.08 NR NR
40 NR NR NR NR NR 1.05 1.30
50 NR 1.47 1.43 1.48 1.13 NR NR
CDa NR NR NR NR NR NR NR
NR means not recorded.
a CD values are the averages of three independent experiments, each with eight repliAdditionally, it has been reported that Nrf2 modifies ROS produc-
tion partly by regulating NQO1 expression [55]. On the other hand,
the NQO1 levels were significantly higher than the non-irradiated
controls, in agreement with the cell culture results (this study).
Notably, the increased levels of ROS in non-irradiated mice treated
with compound 15 are consistent with the increased levels of ROS
following genetic Nrf2 activation by Keap1 knockdown [54].
Importantly however, the increased ROS production that accom-
panies NQO1 induction does not lead to damage, as evidenced by
the lack of increase in the levels of MDA (this study).
2.2.2.2.2. The effect of compound 15 on the hematopoietic system.
To examine the possible role of compound 15 in protecting the
hematopoietic system against irradiation, we measured the pe-
ripheral blood cell counts of red blood cells (RBCs), white blood
cells (WBCs), hemoglobin (HGB) and platelets (PLT). The irradiated
mice exhibited a significant decrease in RBCs, WBCs, HGB and PLT
compared with the control group (Fig. 5). These results are mainly
attributed to the fact that irradiation causes the formation of free
radicals which initiate a chain of events leading to the decline in the
levels of hematological parameters [56]. Indeed, it has been well
established that gamma irradiation induces RBC injury, including
morphological and quantitative changes of RBCs. These alterna-
tions may be partly attributed to radiation-induced oxidative stress
in RBCs. Exposure to radiation results in the formation of reactive
oxygen species (ROS) and reactive nitrogen species (RNS), as well as
DNA damage, which can then lead to severe injury to the he-
matopoietic system [57]. This is in harmony with Wang et al. [58]
who stated that, injury to the hematopoietic system is the most
common injury induced by irradiation. This was attributed to the
effect of ionizing radiation on hematopoietic stem cells and he-
matopoietic progenitor cells, which are principally responsible for
hematopoietic recovery. Treatment of irradiated mice with com-
pound 15 ameliorated the decrease in peripheral blood cells,
particularly RBCs, HGB and PLT. Hence, the antioxidant properties
of compound 15 may contribute to the amelioration of RBC counts
and HGB in irradiated mice. This is consistent with other studies for
antioxidants effects on the hematopoietic system [57,59]. This
might be explained through the promotion effect of radioprotectors
to proliferate hematopoietic stem cells and they also could increase
the levels of leukocyte growth factors [60,61]. Besides, several
potent radioprotectors protect various membrane systems, as well
as hematopoietic stem cells from peroxidative damages, that11 12 13 14 15 16 17 18
NR NR 1.01 NR 1.02 1.01 NR 1.01
0.98 1.01 NR 1.00 NR NR 0.95 NR
NR NR 1.02 NR 1.08 1.01 NR 1.04
0.99 1.02 NR 1.01 NR NR 0.93 NR
NR NR 0.99 NR 1.10 0.99 NR 1.03
0.98 1.00 NR 1.02 NR NR 0.89 NR
NR NR 1.02 NR 1.16 1.00 NR 1.04
0.97 0.98 NR 1.06 NR NR 0.83 NR
NR NR 1.00 NR 1.24 1.06 NR 1.08
0.99 0.99 NR 1.22 NR NR 0.91 NR
NR NR 0.99 NR 1.43 1.28 NR 1.20
1.01 1.08 NR 1.52 NR NR 1.05 NR
NR NR 1.09 NR 1.98 1.53 NR 1.36
1.03 1.18 NR 1.73 NR NR 1.34 NR
NR NR 1.16 NR 2.42 NR NR 1.68
1.14 1.29 NR 1.81 NR NR 1.94 NR
NR NR NR NR 20 NR 50 NR
cate wells of cells, and SD for each data point was within 5% of the value.
Fig. 2. Effect of compound 15 on (A) Nrf2, (B) NQO1, (C) ROS and (D) MDA levels in liver of non-irradiated (control) and irradiated mice after 3 days of irradiation. The results were
expressed as mean ± S.E. Statistical analysis was carried out by one-way ANOVA followed by Bonferroni’s multiple comparison test. *: significantly different from control group, #:
significantly different from irradiated group at p < 0.05. (n ¼ 5).
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against irradiation [62]. Taken all together, these results demon-
strate the protective effect of compound 15 against gamma
radiation.2.3. Molecular docking
Molecular docking was performed to assess the ability ofcompound 15 to block the Kelch domain of Keap1. Through its Kelch
domain, Keap1 binds to Nrf2, promoting its degradation, resulting
in low cytoprotective gene levels [63]. The PDB file: 4IQK was ob-
tained from the Protein Data Bank. The binding site of Kelch domain
has been reported to have five subpockets: P1, P2, P3, P4 and P5
[64]. P1 and P2 are positively charged pockets that contain the
arginine triad (Arg 415, Arg 483 and Arg 380). This triad is crucial
for the selectivity of the molecular recognition, together with a
Fig. 3. A) Survival percent and B) Body weight changes of control, irradiated, com-
pound 15 and compound 15 þ irradiated mice through 30 days after irradiation. The
results were expressed as mean ± S.E. (n ¼ 15). Statistical analysis was carried out by
Kaplan-Meier method followed by the ManteleCox test for survival analysis. Body
weight changes between groups were analyzed by two-way ANOVA followed by
Bonferroni’s post test. *: significantly different from control group, #: significantly
different from irradiated group at p < 0.05.
Fig. 4. Effect of compound 15 on relative liver weight in non-irradiated (control) and
irradiated mice after 3 days of irradiation. The results were expressed as mean ± S.E.
(n ¼ 5). Statistical analysis was carried out by one-way ANOVA followed by Bonfer-
roni’s multiple comparison test. There were no significant differences between groups.
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complex. P1 is formed by residues Arg 415, Ile 461, Gly 462, Phe 478,
Arg 483 and Ser 508. P2 is formed by Ser 363, Arg 380, Asn 382 and
Asn 414. P3 is a neutrally charged pocket composed of Gly 509, Ser
555, Ala 556, Gly 571, Ser 602 and Gly 603. P4 is formed by Tyr 525,
Gln 530 and Tyr 572, whereas P5 is formed by Tyr 334 and Phe 577.
The main interactions observed by the co-crystallized ligand (N,
N0-naphthalene-1,4-diylbis(4-methoxybenzenesulfonamide) are
two cation-pi interaction with Arg 415, piepi interaction with Tyr
525 and two hydrogen bonds with Ser 602 and Ser 508, with S ¼ -
10.11 kcal/mol (Fig. 6). Compound 15 showed the same key in-
teractions exhibited by the co-crystallized ligand. Compound 15
(S ¼ -9.61 kcal/mol, RMSD ¼ 1.34 Å) has adopted a conformation
allowing the presence of two cation-pi interaction between Arg 415
and the aromatic rings in addition to a hydrogen bond with the
methoxy group (Fig. 7), three hydrogen bonds made by ser 508 and
Arg 483 towards the methoxy groups, and another hydrogen bond
between Leu 557 and NH2 group of the sulfonamide. Superimpo-
sition between compound 15 and the co-crystallized ligand showed
that they adopt the same orientation inside the binding site (Fig. 8).
Finally, compound 15 possessing the highest NQO1 inducer activity
(CD ¼ 20 mM) in this series showed the same interactions and the
same orientation of the native ligand inside the receptor, indicating
a possible correlation between those multiple interactions and the
noted higher potency. Based on the above-mentioned results,
compound 15 could possibly bind to Keap1 and disrupt its inter-
action with Nrf2.
The results from this study complement previous reports
showing that the classical electrophilic Nrf2 activator sulforaphane
protects cells, including human retinal pigment epithelial cells,
keratinocytes, and mouse leukemia cells against oxidative damagecaused by oxidative stressors of four different types, namely
menadione, tert-butyl hydroperoxide, 4-hydroxynonenal, and per-
oxynitrite, as well as by exposure to ultraviolet radiation [65,66].
Furthermore, unlike the effects of most direct antioxidants, the
indirect antioxidant effect of sulforaphane, which results from Nrf2
activation, persists for several days after sulforaphane is no longer
present in the cell culture medium. This is because direct antioxi-
dants, such as ascorbic acid, tocopherols, carotenoids, and poly-
phenols, which neutralize ROS and other chemical oxidants are
consumed in these reactions, whereas Nrf2 activation results in
transcriptional upregulation of antioxidant defences, which are
mediated by proteins with long half-lives, often several days. The
new compounds generated in the current study have an additional
advantage in that they are non-electrophilic and are therefore ex-
pected to have a broader therapeutic window compared to elec-
trophilic Nrf2 activators. This is supported by the very low toxicity
of compound 15 in mice. Taken together, these results demonstrate
the powerful effect of Nrf2 activation and induction of NQO1 in
protecting cells and animals against high levels of ROS and pre-
venting ROS-mediated damage. This is of particular relevance to
protecting the hematopoietic system, which is highly sensitive to
ROS.3. Conclusion
In summary, a hybridization strategy was adopted using the
iodinated quinazolinone scaffold and sulfonamide moiety to pro-
duce the 2-((6,8-diiodo-4-oxo-3-(4-sulfamoylphenyl)-3, 4-
dihydroquinazolin-2-yl)thio)-N-(substituted) acetamide de-
rivatives 5e18. Different substitutions were introduced to the
acetamide group to study the structure-activity relationship. All the
compounds were screened for their antioxidant potential using the
NQO1 inducer activity assay. The 3,4,5-trimethoxyphenyl deriva-
tive 15 showed the highest inducer activity in this series
(CD ¼ 20 mM) and had low toxicity (LD50 ¼ 500 mg/kg). Treatment
of gamma-irradiated mice with compound 15 lowered oxidative
stress as evidenced by the lower levels of MDA, ROS and NQO1 in
liver. Furthermore, compound 15 ameliorated the complete blood
picture of irradiated mice, as well as enhanced the survival of mice
Fig. 5. Effect of compound 15 on: (A) RBCs, (B) WBCs, (C) HGB concentration and (D) PLT counts in non-irradiated (control) and irradiated mice after 3 days of irradiation. The results
were expressed as mean ± S.E. (n ¼ 5). Statistical analysis was carried out by one-way ANOVA followed by Bonferroni’s multiple comparison test. *: significantly different from
control group, #: significantly different from irradiated group.
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inside the active site of Keap1 confirmed that it binds in the same
manner as that of the co-crystallized ligands. The inducer activity of
compound 15 in upregulating NQO1 strongly suggests that it could
be used as a lead antioxidant and radiomodulatory agent for further
optimization of the quinazolinone scaffold.4. Materials and methods
4.1. Chemistry
All chemicals were purchased from Sigma-Aldrich and are of AR
grade. Melting points were determined in open capillary on a
Gallen Kamp melting point apparatus (Sanyo Gallen Kamp, UK).
Thin layer chromatography using precoated silica gel plates (Kie-
selgel 0.25 mm, 60 F254, Merck, Germany) was performed with a
solvent system of chloroform/methanol (8:2) to detect the spots by
UV light. IR spectra (KBr disc) were recorded using an FT-IRspectrophotometer (Perkin Elmer, USA). NMR spectrawere scanned
on NMR spectrophotometer (Bruker AXS Inc., Switzerland), oper-
ating at 500 MHz for 1H and 125.76 MHz for 13C. Mass spectra were
recorded on the ISQ LT Thermo Scientific GCMS model (Massa-
chusetts, USA). Chemical shifts are expressed in d-values (ppm)
relative to TMS as an internal standard, using DMSO‑d6 as a solvent.
Elemental analyses were done on a model 2400 CHNSO analyser
(Perkin Elmer, USA). All the values were within ±0.4% of the
theoretical values.4.1.1. 4-(6, 8-diiodo-2-mercapto-4- oxoquinazolin-3(4H)-yl)
benzenesulfonamide (4)
A mixture of 2-amino-3,5-diiodobenzoic acid 3 (3.88 g,
0.01 mol) and 4- isothiocyanatobenzenesulfonamide 2 (2.14 g,
0.01 mol) in absolute ethanol (30 mL) containing 3 drops of trie-
thylamine, was refluxed for 3 h. The solid product formed was
collected by filtration and crystallized from ethanol to give 4.
4: Yield, 88%; m.p. > 300 C. IR (KBr, ʋ cm1): 3311, 3210 (NH2),
Fig. 6. 2D and 3D interaction poses of the N,N0-naphthalene-1,4-diylbis(4-
methoxybenzenesulfonamide showing cation-p, p-p interaction and hydrogen
bonds with the key amino acids inside the binding pocket.
Fig. 7. 2D and 3D interaction pose of compound 15 showing cation-p, p-p interactions
inside the binding pocket of 4IQK.
A.M. Soliman et al. / European Journal of Medicinal Chemistry 200 (2020) 11246783098 (arom.), 1701 (CO), 1618 (CN), 1379, 1160 (SO2). 1H NMR
(DMSO‑d6, d, ppm): 1.97 (s, 1H), 7.86 (d, 2H, J ¼ 7 Hz, AB), 8.06 (d,
2H, J¼ 7 Hz, AB), 8.23 (d,1H, J¼ 2 Hz), 8.58 (d,1H, J¼ 2 Hz),10.05 (s,
2H). 13C NMR (DMSO‑d6, d, ppm): 86.84, 89.74, 118.49, 118.84,
122.99, 127.24 (2), 133.61, 134.21, 136.20, 144.48, 158.31, 165.76,
176.14. Anal. Calcd. for C14H9I2N3O3S2 (584.82): C, 28.73; H, 1.55; N,
7.18. Found: C, 29.02; H, 1.82; N, 7.41.
4.1.2. 3,4-Dihydroquinazolin-sulfonamide derivatives (5-18)
4.1.2.1. General procedure. A mixture of 4 (5.85 g, 0.01 mol) and 2-
chloro-N-substituted acetamide derivatives (0.01 mol) in dry
acetone (30mL) and anhydrous K2CO3 (1.38 g, 0.01mol) was stirred
at room temperature for 18 h, filtered and the solid product formed
was crystallized from dioxane to give 5e18.
4.1.2.2. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-phenylacetamide (5). 5: Yield, 79%;
m.p. > 300 C. IR (KBr, ʋ cm1): 3408, 3310, 3231 (NH, NH2), 3079
(arom.), 2945, 2881 (aliph.), 1702, 1679 (2CO), 1620 (CN), 1349, 1170
(SO2). 1H NMR (DMSO‑d6, d, ppm): 4.17 (s, 2H), 7.03e7.30 (m, 3H),
7.60e7.83 (m, 4H), 8.02 (s, 2H), 8.09 (d, 2H, J ¼ 10 Hz, AB), 8.35 (d,
1H, J¼ 2 Hz), 8.60 (d, 1H, J¼ 2 Hz), 10.12 (s, 1H). 13C NMR (DMSO‑d6,
d, ppm): 29.73, 81.27, 89.61, 118.79 (2), 123.62 (2), 124.33, 127.61,
128.05 (2), 128.80 (2), 133.12, 137.64, 137.90, 139.42, 145.13, 158.92,
163.31, 164.02, 169.81. MS m/z [%]: 718 [Mþ, 29.82], 719 [Mþ1,
19.85], 454 [100]. Anal. Calcd. for C22H16I2N4O4S2 (718.30): C, 36.78;H, 2.25; N, 7.80. Found: C, 37.01; H, 2.51; N, 8.12.4.1.2.3. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-o-tolylacetamide (6). 6: Yield, 81%;
m.p. > 300 C. IR (KBr, ʋ cm1): 3403, 3321, 3216 (NH, NH2), 3098
(arom.), 2956, 2891 (aliph.), 1711, 1681 (2CO), 1631 (CN), 1355, 1188
(SO2). 1H NMR (DMSO‑d6, d, ppm): 2.21 (s, 3H), 4.30 (s, 2H), 7.10
(ddd, 1H, J ¼ 8 & 2.5 Hz), 7.30e7.55 (m, 3H), 7.87 (d, 2H, J ¼ 8.5 Hz,
AB), 8.01 (s, 2H), 8.05 (d, 2H, J ¼ 8.5 Hz, AB), 8.28 (d, 1H, J ¼ 1.5 Hz),
8.55 (d, 1H, J ¼ 1.5 Hz), 9.66 (s, 1H). 13C NMR (DMSO‑d6, d, ppm):
16.32, 26.61, 82.13, 91.41, 120.80 (2), 122.81, 123.90, 124.63, 128.72,
128.91 (2), 129.66, 130.81, 133.54, 134.02, 135.25, 135.87, 147.31,
153.82, 158.10, 159.62, 167.53. Anal. Calcd. for C23H18I2N4O4S2
(732.35): C, 37.72; H, 2.48; N, 7.65. Found: C, 38.04; H, 2.68; N, 7.96.4.1.2.4. 2-((6,8-Diiodo- 4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(m-tolyl)acetamide (7). 7: Yield,
86%; m.p. > 300 C. IR (KBr, ʋ cm1): 3421, 3318, 3207 (NH, NH2),
3095 (arom.), 2978, 2842 (aliph.), 1707, 1675 (2CO), 1625 (CN), 1378,
1145 (SO2). 1H NMR (DMSO‑d6, d, ppm): 2.28 (s, 3H), 4.25 (s, 2H),
Fig. 8. Superimposition of compound 15 (magenta) and the co-crystallized ligand (red)
showed that they adopt the same orientation inside the receptor. (For interpretation of
the references to color in this figure legend, the reader is referred to the Web version of
this article.)
A.M. Soliman et al. / European Journal of Medicinal Chemistry 200 (2020) 112467 96.87 (m, 1H), 7.31e7.56 (m, 3H), 7.82 (d, 2H, J ¼ 6.5 Hz, AB), 8.03 (d,
2H, J ¼ 6.5 Hz, AB), 8.05 (s, 2H), 8.30 (d, 1H, J ¼ 2 Hz), 8.50 (d, 1H,
J ¼ 2 Hz), 10.28 (s, 1H). 13C NMR (DMSO‑d6, d, ppm): 24.13, 27.62,
84.64, 93.71, 117.10, 119.21, 120.63 (2), 122.81, 123.74, 127.62, 128.31
(2), 133.04, 134.22, 135.41, 137.15, 137.90, 146.33, 153.91, 158.03,
161.85, 169.63. Anal. Calcd. for C23H18I2N4O4S2 (732.35): C, 37.72; H,
2.48; N, 7.65. Found: C, 38.07; H, 2.72; N, 7.98.
4.1.2.5. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(p-tolyl)acetamide (8). 8: Yield,
85%; m.p. > 300 C. IR (KBr, ʋ cm1): 3419, 3331, 3197 (NH, NH2),
3089 (arom.), 2995, 2852 (aliph.), 1710,1682 (2CO), 1623 (CN), 1391,
1161 (SO2). 1H NMR (DMSO‑d6, d, ppm): 2.30 (s, 3H), 4.24 (s, 2H),
7.11 (d, 2H, J¼ 6 Hz, AB), 7.61 (m, 2H), 7.90 (d, 2H, J¼ 8 Hz, AB), 8.04
(d, 2H, J ¼ 7 Hz, AB), 8.05 (s, 2H), 8.37 (d, 1H, J ¼ 2 Hz), 8.58 (d, 1H,
J ¼ 2 Hz), 10.43 (s, 1H). 13C NMR (DMSO‑d6, d, ppm): 19.21, 25.64,
80.92, 94.07, 119.21 (2), 120.16 (2), 123.72, 128.35 (2), 129.12 (2),
132.73, 134.61, 134.90, 135.11, 135.85, 145.62, 154.57, 160.61, 161.43,
165.90. MS m/z [%]: 733 [Mþ, 68.30], 681 [100]. Anal. Calcd. for
C23H18I2N4O4S2 (732.35): C, 37.72; H, 2.48; N, 7.65. Found: C, 38.11;
H, 2.80; N, 8.02.
4.1.2.6. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(2-ethylphenyl) acetamide (9).
9: Yield, 79%; m.p. > 300 C. IR (KBr, ʋ cm1): 3402, 3321, 3181 (NH,
NH2), 3092 (arom.), 2982, 2860 (aliph.),1720,1685 (2CO),1619 (CN),
1387, 1142 (SO2). 1H NMR (DMSO‑d6, d, ppm): 1.31 (t, 3H, J ¼ 15 Hz),
2.54 (q, 2H, J ¼ 12 Hz), 4.25 (s, 2H), 7.03 (dd, 1H, J ¼ 8 & 2 Hz), 7.15
(m, 1H), 7.25 (ddd, 1H, J ¼ 7 & 6 Hz), 7.30 (dd, 1H, J ¼ 7 & 2 Hz), 7.76
(d, 2H, J¼ 9 Hz, AB), 8.03 (d, 2H, J¼ 7.5 Hz, AB), 8.04 (m, 2H), 8.32 (d,
1H, J ¼ 2.5 Hz), 8.61 (d, 1H, J ¼ 2.5 Hz), 9.79 (s, 1H). 13C NMR
(DMSO‑d6, d, ppm): 14.67, 24.23, 37.14, 91.81, 101.47, 121.87 (2),
126.36, 126.47, 126.67, 127.59, 128.88, 130.59 (2), 135.59, 135.74,
138.65, 139.69 (2), 146.65, 151.48, 158.80, 159.67, 165.71. MSm/z [%]:
746 [Mþ, 26.98], 747 [Mþ1, 5.94], 368 [100]. Anal. Calcd. for
C24H20I2N4O4S2 (746.38): C, 38.62; H, 2.70; N, 7.51. Found: C, 39.01;
H, 3.01; N, 7.78.
4.1.2.7. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(3-ethylphenyl) acetamide (10).
10: Yield, 75%; m.p. > 300 C. IR (KBr, ʋ cm1): 3412, 3313, 3192
(NH, NH2), 3085 (arom.), 2994, 2853 (aliph.), 1714, 1679 (2CO), 1622
(CN), 1393, 1157 (SO2). 1H NMR (DMSO‑d6, d, ppm): 1.20 (t, 3H, J ¼
15 Hz), 2.58 (q, 2H, J ¼ 12 Hz), 4.21 (s, 2H), 6.98 (ddd, 1H, J ¼ 8 &2 Hz), 7.21e7.48 (m, 2H), 7.70e8.04 (m, 5H), 8.05 (s, 2H), 8.23 (d,1H,
J ¼ 3 Hz), 8.54 (d, 1H, J ¼ 3 Hz), 10.32 (s, 1H). 13C NMR (DMSO‑d6, d,
ppm): 15.21, 24.10, 29.82, 82.60, 92.01, 120.43 (2), 122.71, 128.58,
125.73, 126.02, 126.68, 128.81, 129.12 (2), 133.65, 134.01, 135.28,
135.91, 144.80, 156.02, 160.51, 160.95, 168.12. Anal. Calcd. for
C24H20I2N4O4S2 (746.38): C, 38.62; H, 2.70; N, 7.51. Found: C, 38.31;
H, 2.44; N, 7.20.
4.1.2.8. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(4-ethylphenyl) acetamide (11).
11: Yield, 73%; m.p. > 300 C. IR (KBr, ʋ cm1): 3422, 3330, 3201
(NH, NH2), 3094 (arom.), 2986, 2847 (aliph.), 1710, 1678 (2CO), 1631
(CN), 1384, 1156 (SO2). 1H NMR (DMSO‑d6, d, ppm): 1.15 (t, 3H, J ¼
10 Hz), 2.55 (q, 2H, J ¼ 8 Hz), 4.23 (s, 2H), 7.12 (d, 2H, J ¼ 9 Hz, AB),
7.61 (d, 2H, J ¼ 9 Hz, AB), 7.79 (d, 2H, J ¼ 8.5 Hz), 7.80e8.05 (m, 4H),
8.39 (d, 1H, J ¼ 2 Hz), 8.58 (d, 1H, J ¼ 2 Hz), 10.31 (s, 1H). 13C NMR
(DMSO‑d6, d, ppm): 17.12, 29.40, 29.62, 83.25, 93.04, 120.61 (2),
120.83 (2), 123.10, 127.65 (2), 128.02 (2), 133.71, 135.07, 135.63,
135.80, 140.92, 150.13, 153.81, 160.72, 160.97, 166.32. Anal. Calcd. for
C24H20I2N4O4S2 (746.38): C, 38.62; H, 2.70; N, 7.51. Found: C, 38.97;
H, 2.96; N, 7.78.
4.1.2.9. 2-((6,8-Diiodo- 4-oxo-3-(4-sulfamoylphenyl)-3, 4-
dihydroquinazolin-2-yl)thio)-N -(4-methoxyphenyl) acetamide (12).
12: Yield, 79%; m.p. > 300 C. IR (KBr, ʋ cm1): 3397, 3325, 3194
(NH, NH2), 3087 (arom.), 2990, 2852 (aliph.), 1716, 1684 (2CO), 1627
(CN),1396,1140 (SO2). 1H NMR (DMSO‑d6, d, ppm): 3.75 (s, 3H), 4.29
(s, 2H), 6.87 (d, 2H, J ¼ 9 Hz, AB), 7.56 (d, 2H, J ¼ 9 Hz, AB), 7.78 (d,
2H, J ¼ 7 Hz, AB), 7.95 (d, 2H, J ¼ 7 Hz), 8.04 (s, 2H), 8.27 (d, 1H,
J¼ 2.5 Hz), 8.61 (d, 1H, J¼ 2.5 Hz), 10.20 (s, 1H). 13C NMR (DMSO‑d6,
d, ppm): 29.43, 54.26, 83.03, 91.67, 112.01 (2), 118.33 (2), 123.14 (2),
123.85, 127.82 (2), 129.64, 134.12, 134.83, 135.90, 150.23, 156.71,
157.42, 160.04, 161.62, 169.31. Anal. Calcd. for C23H18I2N4O5S2
(748.35): C, 36.91; H, 2.42; N, 7.49. Found: C, 37.27; H, 2.70; N, 7.82.
4.1.2.10. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(4-ethoxyphenyl) acetamide (13).
13: Yield, 78%; m.p. > 300 C. IR (KBr, ʋ cm1): 3385, 3295, 3188
(NH, NH2), 3096 (arom.), 2979, 2844 (aliph.), 1705,1680 (2CO),1608
(CN), 1387, 1148 (SO2). 1H NMR (DMSO‑d6, d, ppm): 1.27 (t, 3H, J ¼
12 Hz), 3.97 (q, 2H, J¼ 10 Hz), 4.21 (s, 2H), 6.89 (d, 2H, J¼ 10 Hz, AB),
7.39 (d, 2H, J ¼ 10 Hz, AB), 7.76 (d, 2H, J ¼ 8 Hz, AB), 8.03e8.10 (m,
4H), 8.29 (d, 1H, J ¼ 2 Hz), 8.62 (d, 1H, J ¼ 2 Hz), 10.29 (s, 1H). 13C
NMR (DMSO‑d6, d, ppm): 15.21, 29.63, 62.04, 83.72, 92.57, 115.03
(2), 120.61 (2), 121.40 (2), 122.74, 127.66 (2), 129.52, 134.67, 134.91,
135.78, 146.83, 154.02, 155.25, 160.12, 162.46, 169.60. Anal. Calcd.
for C24H20I2N4O5S2 (762.38): C, 37.81; H, 2.64; N, 7.35. Found: C,
38.20; H, 3.00; N, 7.65.
4.1.2.11. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(3,5-dimethoxyphenyl) acetamide
(14). 14: Yield, 67%; m.p. > 300 C. IR (KBr, ʋ cm1): 3256, 3209,
3142 (NH, NH2), 3065 (arom.), 2912, 2844 (aliph.), 1676,1663 (2CO),
1608 (CN), 1385, 1161 (SO2). 1H NMR (DMSO‑d6, d, ppm): 3.74 (s,
6H), 4.21 (s, 2H), 6.25 (dd, 1H, J ¼ 3 & 1.5 Hz), 6.87 (dd, 2H, J ¼ 3 &
1.5 Hz), 7.77 (d, 2H, J ¼ 9 Hz, AB), 8.04 (d, 2H, J ¼ 9 Hz, AB), 8.05 (s,
2H), 8.34 (d, 1H, J¼ 2.5 Hz), 8.63 (d, 1H, J¼ 2.5 Hz), 10.38 (s, 1H). 13C
NMR (DMSO‑d6, d, ppm): 31.32, 55.56 (2), 91.66, 95.96, 98.12, 101.11
(2), 121.92 (2), 127.61, 130.64 (2), 135.64, 138.77 (2), 140.93, 146.14,
151.43, 158.86, 159.59 (2), 160.90, 165.20. Anal. Calcd. for
C24H20I2N4O6S2 (778.38): C, 37.03; H, 2.59; N, 7.20. Found: C, 37.34;
H, 2.83; N, 7.43.
4.1.2.12. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(3,4,5-trimethoxyphenyl) acetamide
A.M. Soliman et al. / European Journal of Medicinal Chemistry 200 (2020) 11246710(15). 15: Yield, 80%; m.p. > 300 C. IR (KBr, ʋ cm1): 3416, 3319,
3200 (NH, NH2), 3093 (arom.), 2982, 2822 (aliph.), 1689, 1666
(2CO), 1616 (CN), 1370, 1151 (SO2). 1H NMR (DMSO‑d6, d, ppm): 3.70
(s, 6H), 3.81 (s, 3H), 4.31 (s, 2H), 6.90 (d, 2H, J ¼ 3 Hz), 7.78 (d, 2H,
J ¼ 9 Hz, AB), 8.04 (s, 2H), 8.05 (d, 2H, J ¼ 9 Hz), 8.28 (d, 1H,
J ¼ 2.5 Hz, AB), 8.54 (d, 1H, J ¼ 2.5 Hz), 10.36 (s, 1H). 13C NMR
(DMSO‑d6, d, ppm): 27.23, 55.60 (2), 61.32, 82.74, 95.07, 101.41 (2),
119.60 (2), 121.82, 130.74 (2), 131.90, 133.81, 134.15, 134.67, 134.92,
146.04, 151.32 (2), 153.50, 160.01, 160.73, 166.37. MS m/z [%]: 809
[Mþ, 15.75], 456 [100]. Anal. Calcd. for C25H22I2N4O7S2 (808.40): C,
37.14; H, 2.74; N, 6.93. Found: C, 37.44; H, 3.03; N, 7.29.
4.1.2.13. 2-((6,8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3,4-
dihydroquinazolin-2-yl)thio)-N-(2-methyl-4-nitrophenyl) acetamide
(16). 16: Yield, 74%; m.p. > 300 C. IR (KBr, ʋ cm1): 3313, 3265,
3203 (NH, NH2), 3055 (arom.), 2943, 2811 (aliph.), 1683,1660 (2CO),
1621 (CN), 1530, 1370 (NO2), 1397, 1155 (SO2). 1H NMR (DMSO‑d6, d,
ppm): 2.39 (s, 3H), 4.30 (s, 2H), 7.72 (d, 1H, J ¼ 9.5 Hz), 7.88 (d, 2H,
J ¼ 8 Hz, AB), 7.90e8.05 (m, 6H), 8.26 (d, 1H, J ¼ 3 Hz), 8.59 (d, 1H,
J ¼ 3 Hz), 10.27 (s, 1H). 13C NMR (DMSO‑d6, d, ppm): 18.05, 27.34,
83.69, 92.03, 106.32, 120.85, 121.71 (2), 125.83, 127.61, 130.64 (2),
133.72, 134.80, 134.92, 135.01, 141.42, 141.94, 147.56, 154.02, 160.82,
161.04, 167.42. Anal. Calcd. for C23H17I2N5O6S2 (777.35): C, 35.54; H,
2.20; N, 9.01. Found: C, 35.78; H, 2.57; N, 9.32.
4.1.2.14. 2-((6, 8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3, 4-
dihydroquinazolin-2-yl)thio)- N-(2-methyl-6-nitrophenyl) acet-
amide (17). 17: Yield, 70%; m.p. > 300 C. IR (KBr, ʋ cm1): 3329,
3283, 3174 (NH, NH2), 3087 (arom.), 2952, 2828 (aliph.), 1680, 1662
(2CO), 1615 (CN), 1545, 1340 (NO2), 1376, 1155 (SO2). 1H NMR
(DMSO‑d6, d, ppm): 2.21 (s, 3H), 4.27 (s, 2H), 7.34 (dd, 1H, J ¼ 9 &
6 Hz), 7.76 (dd, 1H, J ¼ 9 & 2.5 Hz), 7.82 (d, 2H, J ¼ 10 Hz), 8.01e8.10
(m, 5H), 8.27 (d,1H, J¼ 2.5 Hz), 8.67 (d,1H, J¼ 2.5 Hz), 10.02 (s, 1H).
13C NMR (DMSO‑d6, d, ppm): 18.17, 36.90, 91.83, 101.40, 121.87 (2),
122.70, 127.43, 127.63, 128.79, 130.67 (2), 135.49, 135.62 (2), 137.85
(2), 138.68, 146.93, 151.50, 158.34, 159.67, 165.87. MS m/z [%]: 777
[Mþ, 4.30], 64 [100]. Anal. Calcd. for C23H17I2N5O6S2 (777.35): C,
35.54; H, 2.20; N, 9.01. Found: C, 35.80; H, 2.47; N, 9.33.
4.1.2.15. 2-((6, 8-Diiodo-4-oxo-3-(4-sulfamoylphenyl)-3, 4-
dihydroquinazolin-2-yl)thio)- N-(2,4-dinitrophenyl) acetamide (18).
18: Yield, 66%; m.p. > 300 C. IR (KBr, ʋ cm1): 3432, 3303, 3165
(NH, NH2), 3058 (arom.), 2961, 2850 (aliph.), 1690, 1683 (2CO),1608
(CN), 1537, 1361 (NO2), 1388, 1161 (SO2). 1H NMR (DMSO‑d6, d,
ppm): 4.31 (s, 2H), 7.75 (d, 2H, J ¼ 8 Hz, AB), 7.90 (d, 1H, J ¼ 10 Hz),
8.00e8.04 (m, 2H), 8.04 (d, 2H, J¼ 8 Hz, AB), 8.29 (d, 1H, J¼ 2.5 Hz),
8.30e8.34 (m, 3H), 11.21 (s, 1H). 13C NMR (DMSO‑d6, d, ppm): 29.21,
86.23, 102.13, 117.69, 121.03 (2), 122.12, 124.25, 127.43 (2), 131.16,
134.64 (2), 139.50 (2), 142.62, 144.12, 149.04, 154.91, 160.24, 165.65,
167.45. Anal. Calcd. for C22H14I2N6O8S2 (808.32): C, 32.69; H, 1.75;
N, 10.40. Found: C, 32.36; H, 1.47; N, 10.18.
4.2. Biological evaluation
4.2.1. NQO1 in vitro inducer activity
Hepa1c1c7 murine hepatoma cells were grown in a humidified
atmosphere at 37 C, 5% CO2. The cells were tested routinely to
ensure that they were mycoplasma-free. The a-minimum essential
medium (a-MEM) supplemented with 10% (v/v) heat- and
charcoal-inactivated (1 g/100 mL, 90 min at 55 C) fetal bovine
serum was used. For evaluation of the potential NQO1 inducer ac-
tivity, cells (104/well) were grown in transparent flat-bottom
plastic 96-well plates for 24 h, after which the cell culture me-
dium was replaced with fresh medium containing each inducer
(dissolved in DMSO and diluted in the medium 1:1000), and thecells were grown for further 48 h. Three replicates of each treat-
ment of eight serial dilutions of inducers were used. The final DMSO
concentration in the cell culture medium was maintained at 0.1%
(v/v) in all wells. Cell lysates were prepared in digitonin and the
specific activity of NQO1 was determined using menadione as a
substrate as described [67,68]. Briefly, the cell culture mediumwas
removed from each well, and the cells were washed three times
with 200 mL of phosphate buffered saline (PBS), and subsequently
lysed in 75 mL of digitonin suspension in the presence of EDTA for
20 minwith shaking. Of the cell lysate, 20 mL was transferred to the
well of a new plate and used to determine the protein concentra-
tion by adding 300 mL of bicinchoninic acid reagent and measuring
the reaction product spectrophotometrically in a 96-well plate
reader at 550 nm after 30 min incubation at room temperature. The
remaining 55 mL of the cell lysate was used to measure the enzyme
activity of NQO1. This was done by addition of 200 mL of enzyme
assay buffer, containing NADPH-generating system (glucose-6-
phosphate, glucose-6-phosphate dehydrogenase, NADP) that
maintained a constant NADPH concentration, FAD, menadione (2-
methyl-1,4-naphthoquinone, a quinone that is reduced to mena-
diol by NQO1 in the presence of NADPH), and MTT (3-[4,5-
dimethylthiazo-2-yl]-2,5-diphenyltetrazolium bromide; a tetrazo-
lium dye that is reduced non-enzymatically to a formazan dye by
menadiol). The reactionwas terminated after 5 min by the addition
of dicumarol (a potent inhibitor of NQO1), and the reduced for-
mazan dye was measured spectrophotometrically at 610 nm. The
Concentration that Doubles the specific activity of NQO1 (CD value)
was used as a measure of inducer potency. Mean values for the
eight replicate wells are shown for each data point. The standard
deviation for each data point was within 5% of the mean value. The
classical NQO1 inducer sulforaphane was included as a positive
control in each bioassay and was consistently giving a CD value of
0.2 mM.
4.2.2. In vivo evaluation
4.2.2.1. Animals. Eight-week old Swiss albino male mice (20e25 g)
were supplied from the breeding unit of the National Center for
Radiation Research and Technology (NCRRT), Cairo, Egypt. They
were housed in the laboratory room for one week prior to the
experiment for acclimatization to the lab environment. Water and
food were allowed ad libitum. Mice were kept under controlled
conditions: room temperature of 25 ± 5 C, humidity (60 ± 5%),
alternating 12 h dark and 12 h light cycle. Animals were treated
gently; squeezing, pressure and tough handling were avoided. All
animal procedures were performed in accordance with the Ethics
Committee for Animal Experimentations, Faculty of Pharmacy,
Cairo University, which complies with the Guide for the Care and
Use of Laboratory Animals issued by the US National Institutes of
Health (NIH Publication No. 85-23, revised 2011).
4.2.2.2. Irradiation process. Mice were exposed to whole-body
gamma radiation as a single dose of 7 Gy using Canadian Gamma
Cell-40 biological irradiator (137Cs) located at the NCRRT, Cairo,
Egypt and the dose rate was 0.655 rad/s.
4.2.2.3. Acute toxicity study. The median lethal dose (LD50) of the
most promising compound, 15 was determined according to Chi-
nedu et al. [69].
4.2.2.4. Experimental design. Eighty mice were randomly classified
into four groups. First (control) group was injected i.p. with 10%
DMSO, daily, for 5 days. Second (irradiated) group was treated as
control, and after 1 h from last DMSO injection, the mice were
irradiated at a dose of 7 Gy. Third (Compound 15) group; received
50 mg/kg/day i.p. (1/10 LD50) of compound 15, daily for 5 days.
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group then on the last day, after 1 h of injection, mice exposed to
7 Gy gamma radiation. On the third day, five mice from each group
(n ¼ 5) were weighed and anesthetized using urethane (1.2 mg/kg
i.p) [70]. Then the blood samples were collected by cardiac punc-
ture. At that time, they were euthanized by cervical dislocation.
Each blood sample was collected into EDTA coated tubes for com-
plete blood picture. Liver tissues were rinsed with ice-cold saline,
dried on a filter paper and weighed to calculate the relative liver/
body weight ratio. Then, it was homogenized in ice-cold 0.1 M
phosphate buffer saline (pH 7.4) and stored at 80 C till used for
subsequent biochemical analysis. The residual of mice in all the
groups was monitored on a daily basis for 30 days to check the
survival rate, as well as their body weight, were recorded weekly to
estimate the changes in body weight.
4.2.2.5. Biochemical parameters investigated in liver homogenate.
Liver homogenates were used for measuring the level of Nrf2 using
colorimetric cell-based Elisa kit (OKAG00918) Aviva systems
biology (San Diego, CA., USA), as well as the level of NAD(P)H:
quinone oxidoreductase 1 (NQO1) was measured using an ELISA Kit
(OKCD02727) Aviva Systems Biology (San Diego, CA., USA). Liver
lipid peroxides were determined bymeasuringMDA as an indicator
according to the method of Yoshioka et al. [71]. The generation of
ROS in liver tissues was measured according to a modified tech-
nique of Vrablic et al. [72].
4.2.2.6. Hematological analysis. Complete blood count with
platelet count was determined using the automatedmicro-analyzer
(BC-2800 Mindray, China).
4.2.2.7. Statistical analysis. Data were analyzed using Prism 5.03
(GraphPad, San Diego, CA, USA) and expressed as means ± standard
error. Comparisons between groups were analyzed by one-way
analysis of variance (ANOVA) followed by Bonferroni’s multiple
comparison test. Survival was analyzed by the KaplaneMeier
method followed by the ManteleCox (log rank) test. Body weight
changes between groups through 30 days were analyzed by two-
way ANOVA followed by Bonferroni’s post test. P < 0.05 was
considered to represent statistically significant differences.
4.3. Molecular docking
The molecular modeling studies were fulfilled by the Molecular
Operating Environment software (MOE, 10.2008). The receptor was
chosen from the protein data bank; 4IQK that represents Keap1 co-
crystallized with N,N0-naphthalene-1,4-diylbis(4-
methoxybenzenesulfonamide. The protein was prepared for dock-
ing by ignoring water in the receptor. Hydrogen atoms were added
to the structure with their standard geometry. The co-crystallized
ligand was used to determine the binding site. Triangle Matcher
placement method and dG scoring function were used for docking.
Energy minimizations were performed with an RMSD gradient of
0.1 kcal mol1Å1with the MMFF94X force field and the partial
charges were automatically calculated. Validation of the docking
protocol was performed by re-docking of the co-crystallized ligands
into the active site of Keap1 protein followed by docking of com-
pound 15. The obtained data were used to interpret the ligand-
protein interactions at the Nrf2-binding site.
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